阿托伐他汀治疗非缺血性心力衰竭疗效观察

目的 探讨阿托伐他汀钙治疗非缺血性心力衰竭疗效.方法 60例扩张型心肌病伴心力衰竭患者随机分为阿托伐他汀钙组及对照组,每组各30例.分别于治疗前、治疗3个月、治疗12个月进行心功能分级（NYHA分级）以及检测左室射血分数（LVEF）、血C反应蛋白（CRP）、总胆固醇（TC）和低密度脂蛋白（LDL）.结果 在治疗3个月和12个月后阿托伐他汀组和对照组CRP、TC及LDL的水平均降低,EF、NYHA分级的水平均增加,但阿托伐他汀组在CRP、TC及LDL水平的降低和在EF、NYHA分级水平的增加方面明显优于对照组（ P 〈0.05）.阿托伐他汀组EF与CRP水平呈显著负相关（ P 〈0.01）,而EF与TC、LDL呈零相关;对照组EF与CRP、TC、LDL水平呈零相关.结论 （1）非缺血性心力衰竭患者在常规治疗的基础上加用阿托伐他汀可显著改善左室功能,降低血CRP水平.（2）阿托伐他汀改善非缺血性心力衰竭可能与其具有降血脂以外的多效作用有关.

Atorvastatin treatment efficacy of non-ischemic heart failure

Objective To study the treatment of atorvastatin calcium effect of non - ischemic heart failure. Methods 60 patients with dilated cardiomyopathy with heart failure were randomly assigned to atorvastatin calcium group and control group, 30 cases in each. Respectively on before treatment, treatment 3 months, 12 months for cardiac function NYHA hierarchical） and level （test left ventricular ejection fraction （LVEF） , blood c -reactive protein （CRP）, total cholesterol （TC） and low - density lipoprotein （LDL）. Results In the treatment of 3 months and 12 months atorvastatin group and control group CRP, TC, and LDL, lower levels were, EF, NYHA classification levels were increased, but the atorvastatin group CRP, TC and lower LDL levels and in EF, NYHA classification in terms of increased levels higher than the control group （ P 〈0. 05 ）. 2. Atorvastatin group EF, CRP levels were significantly negatively correlated （ P 〈 0.01 ）, while EF and TC, LDL was zero correlation ; control group, EF and CRP, TC, LDL levels were zero correlation. Conclusion （ 1 ） Non - ischemic heart failure patients in the conventional treatment based on the use of atorvastatin can significantly improve left ventricular function, lower blood CRP levels. （2） Atorvastatin improve the non - isehemie heart failure may be associated with the role of lipid - lowering effect than the more relevant.